Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

Our heart muscle is studded with tiny dyads, intricately designed structures that manage incoming electrical signals and ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

Conformational changes on the capsid may be the cause of the charge differences between empty and full AAV capsids.

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering AAV capsids.

Ocuphire Pharma has acquired Opus Genetics, creating a new entity focused on gene therapies, which will trade as Opus ...

Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important ...

Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.